| Title |
Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience
|
|---|---|
| Published in |
Clinical Kidney Journal, October 2017
|
| DOI | 10.1093/ckj/sfx105 |
| Pubmed ID | |
| Authors |
Soumita Bagchi, Arun Kumar Subbiah, Dipankar Bhowmik, Sandeep Mahajan, Raj Kanwar Yadav, Mani Kalaivani, Geetika Singh, Amit Dinda, Sanjay Kumar Agarwal |
| Abstract |
Persistent significant proteinuria has been associated with increased risk of progression to end-stage kidney disease in patients with idiopathic membranous nephropathy (IMN). Rituximab (RTX) therapy has given encouraging results in IMN, but most of the studies have used a higher dose, which is limited by the high cost as well as a potential increased risk of infections. Our study aimed to assess the efficacy and safety of low-dose RTX in patients with immunosuppression-resistant IMN. A total of 21 patients with treatment-resistant IMN treated with RTX from 2015 to 2016 at our center were included in the study. They received two doses of RTX (500 mg each) infusion 7 days apart. CD19 count was performed after 4 weeks. A single dose of RTX was repeated after 4-6 weeks if CD19 count was not depleted. The mean standard deviation age of patients was 33.3 ± 12.3 years and 33.3% were females. Mean proteinuria before RTX therapy was 6.2 ± 2.2 g/day, serum creatinine was 0.9 ± 0.3 mg/dL and estimated glomerular filtration rate (eGFR) was 95.8 ± 26.9 mL/min/1.73 m2. All the patients were non-responders to prior immunosuppressive treatment. Twenty (95.2%) patients achieved targeted CD19 depletion with two doses of RTX. One patient required one additional RTX dose due to inadequate B-cell suppression. A total of 13 (61.9%) patients achieved remission with RTX therapy: 4 (19.0%) complete and 9 (42.9%) partial remission. Patients who did not respond to RTX had a significantly lower baseline eGFR compared with those who achieved remission (P = 0.022). One patient developed respiratory tract infection following RTX during the follow-up, which responded to a course of oral antibiotics. During median follow-up of 13.1 (10-23.9) months, four (19%) patients had deterioration in renal function and one patient relapsed after achieving partial remission. Renal survival was significantly better in patients who responded to RTX therapy as compared with those who did not achieve remission (P = 0.0037). Low-dose RTX therapy is effective and safe in immunosuppression-resistant IMN. |
X Demographics
The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 16% |
| Mexico | 2 | 11% |
| India | 2 | 11% |
| Ecuador | 1 | 5% |
| Malaysia | 1 | 5% |
| Venezuela, Bolivarian Republic of | 1 | 5% |
| United Kingdom | 1 | 5% |
| Unknown | 8 | 42% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 68% |
| Practitioners (doctors, other healthcare professionals) | 4 | 21% |
| Science communicators (journalists, bloggers, editors) | 2 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 18% |
| Other | 2 | 12% |
| Student > Ph. D. Student | 2 | 12% |
| Student > Bachelor | 2 | 12% |
| Librarian | 1 | 6% |
| Other | 2 | 12% |
| Unknown | 5 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 35% |
| Nursing and Health Professions | 1 | 6% |
| Social Sciences | 1 | 6% |
| Agricultural and Biological Sciences | 1 | 6% |
| Unknown | 8 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 July 2019.
All research outputs
#2,778,425
of 23,340,595 outputs
Outputs from Clinical Kidney Journal
#460
of 1,770 outputs
Outputs of similar age
#54,370
of 325,504 outputs
Outputs of similar age from Clinical Kidney Journal
#13
of 40 outputs
Altmetric has tracked 23,340,595 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,770 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.4. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,504 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.